about
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity.Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin-homing and systemic T-cell populations.Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues.Atopic Dermatitis in Diverse Racial and Ethnic Groups - Variations in Epidemiology, Genetics, Clinical Presentation, and Treatment.Conjunctivitis in dupilumab clinical trialsThe oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled studyBaricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
P50
Q39150394-68EF6093-0D3F-4D9E-B0A2-B4F7C67B795CQ47120280-298A1911-2932-4DD3-A0D0-B8682584D9BCQ47691884-CC205D11-F068-4D24-AB9D-4A96DB2C3A59Q48298664-849F6844-FFD0-4435-9DC3-834E413BC96EQ49861324-0730EF45-20BC-4A4F-BB43-00DA67571C1BQ92239928-0D30C762-DB34-4FB4-8EFC-376AB23B3472Q92665324-34662043-E7D4-46DC-9BDB-63DA76E051A1Q93033470-41D63EFD-680B-44C9-A5B3-F4E56438C316
P50
description
researcher (ORCID 0000-0002-9363-324X)
@en
wetenschapper
@nl
name
E Guttman-Yassky
@en
E Guttman-Yassky
@nl
type
label
E Guttman-Yassky
@en
E Guttman-Yassky
@nl
prefLabel
E Guttman-Yassky
@en
E Guttman-Yassky
@nl
P31
P496
0000-0002-9363-324X